NCT06892951: CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 100 planned
- Started
- 2 Dec 2025
- Primary completion
- Dec 2026
- Arms
- Part 2 - randomized study (group 1), Part 1 - open study
- Results
- None posted
- 25 Mar 2025: Trial registered
- 2 Dec 2025: Trial started